HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
Rhea-AI Summary
HOOKIPA (OTCID: HOOK) completed the sale of its immuno-oncology assets to NeoTrail Therapeutics, transferring the HB-200 (eseba-vec) and HB-700 development programs.
The asset purchase agreement was signed on January 28, 2026, and the transaction closed on March 20, 2026. The purchase price remains undisclosed.
Positive
- Completed sale of HB-200 and HB-700 oncology programs to NeoTrail
- Asset purchase agreement signed on January 28, 2026
- Transaction closing date: March 20, 2026
Negative
- Purchase price for the asset sale was not disclosed
News Market Reaction – HOOK
In the Mar 26 session, HOOK gained 0.93%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Oncology asset sale | Neutral | +4.0% | Announced sale of HB-200 and HB-700 oncology assets to NeoTrail. |
| Oct 31 | HBV/HIV asset sale | Neutral | +0.6% | Completed sale of HB-400 and certain HB-500 assets to Gilead. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent asset sales (to NeoTrail and Gilead) were followed by modest positive 1-day price reactions.
Over the past year, HOOKIPA has repeatedly monetized pipeline assets. On Feb 3, 2026, it announced the sale of its immuno-oncology programs HB-200 and HB-700 to NeoTrail, with the stock up 4% the next day. Earlier, on Oct 31, 2025, it completed the sale of HBV and HIV assets (HB-400 and HB-500 components) to Gilead, with a 0.57% positive reaction. Today’s completion of the NeoTrail transaction follows this ongoing asset-divestment trajectory.
Key Terms
immuno-oncology medical
oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics
NEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. The asset purchase agreement was signed on January 28, 2026, and the closing of the transaction occurred on March 20, 2026.
About HB-200
Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PICV), collectively referred to as “HB-200,” attenuated viral vectors, which on their own are replicating-based therapeutics expressing a non-oncogenic, but highly immunogenic, E7E6 fusion protein from HPV16. Positive preliminary data from a Phase 2 trial (NCT04180215) of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16 positive head and neck cancers in the first line setting was presented in November 2024 at the Society for Immunotherapy of Cancer (SITC) Conference. Trial close out activities were completed before the end of 2025. HB-200 received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency. HB-200 was developed using HOOKIPA’s proprietary arenavirus platform.
About HB-700
HB-700 is an investigational arenaviral immunotherapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers. HB-700 is a replicating 2-vector therapy that targets the most prevalent KRAS mutations (G12D, G12V, G12R, G12C and G13D) and has the potential to benefit more patients than single mutation inhibitors. HB-700 received Investigational New Drug application clearance from the Food and Drug Administration in April 2024 and is Phase 1 ready, with clinical trial material manufacturing completed.
Availability of Other Information About HOOKIPA
Investors and others should note that HOOKIPA announces material financial information to investors using the Company’s investor relations website, www.ir.hookipapharma.com, OTC Markets filings, press releases, public conference calls and webcasts. HOOKIPA uses these channels, as well as social media, to communicate with investors and the public about the company, and other issues. It is possible that the information HOOKIPA posts on social media could be deemed to be material information. Therefore, investors, the media, and others interested in HOOKIPA are encouraged to review the information on the social media channels listed on the Company’s investor relations website.
For further information, please contact: IR@hookipapharma.com